These tumors have more frequent instances of chromothripsis [52,67], increased frequency of mutation in genes responsible for overall genomic stability [52], and increased frequency of CDK4 and CDKN2A/B alterations than their IDH-mutant lower-grade glioma counterparts, which corresponds to their worse clinical outcomes in terms of PFS and OS, but unlike within the lower-grade cohorts, we found no statistically significant prognostic effect of harboring these alterations in GBM [52]. The gene discussed is CDK4; the disease is glioblastoma.